ABIVAX Société Anonyme (ABVX) Expected to Announce Quarterly Earnings on Monday

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) is anticipated to release its earnings data before the market opens on Monday, June 2nd. Analysts expect ABIVAX Société Anonyme to post earnings of ($1.59) per share and revenue of $3.11 million for the quarter.

ABIVAX Société Anonyme Price Performance

ABIVAX Société Anonyme stock traded down $0.01 during trading hours on Wednesday, hitting $5.68. The stock had a trading volume of 290,200 shares, compared to its average volume of 140,806. The business's 50 day simple moving average is $6.32 and its 200-day simple moving average is $7.02. ABIVAX Société Anonyme has a one year low of $4.77 and a one year high of $14.71.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of hedge funds have recently added to or reduced their stakes in ABVX. Millennium Management LLC lifted its holdings in shares of ABIVAX Société Anonyme by 6.0% in the first quarter. Millennium Management LLC now owns 987,414 shares of the company's stock valued at $6,171,000 after purchasing an additional 56,235 shares in the last quarter. Woodline Partners LP lifted its holdings in shares of ABIVAX Société Anonyme by 319.5% in the first quarter. Woodline Partners LP now owns 201,924 shares of the company's stock valued at $1,262,000 after purchasing an additional 153,788 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of ABIVAX Société Anonyme by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of ABIVAX Société Anonyme by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ABVX. JMP Securities reissued a "market outperform" rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research note on Wednesday, April 30th. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price target on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.